What is Retatrutide?
Retatrutide is a first-in-class triple agonist of GIP, GLP-1, and glucagon receptors developed by Eli Lilly. In Phase II clinical trials, it produced an average 24.2% body weight loss at 48 weeks — the highest ever recorded for a pharmaceutical weight loss agent, surpassing even Tirzepatide. It represents the next generation of metabolic peptide therapy.
Mechanism of Action
Retatrutide simultaneously activates three receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced GLP-1 effects, adipose metabolism), and glucagon (increased energy expenditure, fat oxidation). The glucagon component is what sets it apart — it increases metabolic rate and fat burning beyond what dual GIP/GLP-1 agonists achieve.
Retatrutide Dosing Protocol
Phase II doses: 1–12 mg/week subcutaneous. Titration schedule: 2 mg/week for 4 weeks, then increase by 2 mg every 4 weeks to target dose. Research doses typically 4–12 mg/week.
Want a personalized protocol? Tell PepBot your goals, health status, and experience level for a custom Retatrutide protocol.
Retatrutide Benefits
Side Effect Profile
Nausea, vomiting, diarrhea (similar to other GLP-1 agonists but manageable with titration). Potential hypoglycemia. Not yet FDA-approved — Phase III trials ongoing.
Retatrutide Stacking Guide
Retatrutide works synergistically with these compounds. Click any to learn more, or ask PepBot to build you a complete stack.
Research & Citations
Frequently Asked Questions about Retatrutide
Is Retatrutide better than Tirzepatide?
Still have questions about Retatrutide?
PepBot has encyclopedic knowledge of Retatrutide — dosing, stacking, interactions, latest research, and personalized protocols. Ask anything.